Inovio Pharmaceuticals (INO) EBITDA Margin (2010 - 2025)
Inovio Pharmaceuticals (INO) posted EBITDA Margin of 38336.97% for Q1 2025, down 120.19% sequentially from 17410.77% in Q4 2024.
Inovio Pharmaceuticals (INO) EBITDA Margin (2010 - 2025) Analysis & Trends
Inovio Pharmaceuticals has reported EBITDA Margin for 16 years, with the latest figure at 38336.97% in Q1 2025.
- Quarterly EBITDA Margin changed N/A year-over-year to 38336.97% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 132871.32% (down 8125440.0% YoY) and the FY2025 annual result came in at 132871.32%, down 8125440.0% from the prior year.
- EBITDA Margin slipped to 38336.97% in Q1 2025 per INO's latest filing, from 17410.77% in the prior quarter.
- Over five years, EBITDA Margin peaked at 390.61% in Q3 2022 and troughed at 44876.83% in Q4 2022.
- A 5-year average of 23434.95% and a median of 20553.16% in 2021 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 2016255 bps in 2022, down 3230307 bps in 2022.
- Over 5 years, EBITDA Margin stood at 12573.76% in 2021, then slumped by 257 bps to 44876.83% in 2022, then surged by 41 bps to 26686.29% in 2023, then surged by 35 bps to 17410.77% in 2024, then slumped by 120 bps to 38336.97% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 38336.97%, 17410.77%, and 32945.87% for Q1 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Inovio Pharmaceuticals | 97.94 Mn | 97.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -38,336.97% |
| Dec 31, 2024 | -17,410.77% |
| Jun 30, 2024 | -32,945.87% |
| Dec 31, 2023 | -26,686.29% |
| Sep 30, 2023 | -9,152.63% |
| Jun 30, 2023 | -16,391.97% |
| Mar 31, 2023 | -38,238.24% |
| Dec 31, 2022 | -44,876.83% |
| Sep 30, 2022 | -390.61% |
| Jun 30, 2022 | -13,276.13% |
| Mar 31, 2022 | -36,033.33% |
| Dec 31, 2021 | -12,573.76% |
| Sep 30, 2021 | -20,553.16% |
| Jun 30, 2021 | -30,496.56% |
| Mar 31, 2021 | -14,161.05% |
| Dec 31, 2020 | -525.74% |
| Sep 30, 2020 | -15,382.23% |
| Jun 30, 2020 | -12,418.60% |
| Mar 31, 2020 | -1,901.06% |
| Dec 31, 2019 | -10,884.56% |